The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist (LAMA) or a Leukotriene Receptor Antagonist (LTRA) on top of a moderate-dose ...

This article was originally on a blog post platform and may be missing photos, graphics or links. See About archive blog posts. This week’s issue of the prestigious medical journal the Lancet is ...

Asthma is a common prevalent chronic respiratory illness that affects millions of people all over the world in every age group. Asthma is defined as inflamed and constricted airways, causing repeated ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...

FeNO testing is increasingly recognized as a key first step in asthma assessment under the updated UK guidelines.

Due to eczema, asthma and allergies being so closely connected, coordinated care plays a critical role in long-term outcomes. Allergists are uniquely trained to manage these conditions together rather ...

Despite the name, cardiac asthma isn’t a type of asthma. It refers to breathing difficulty caused by fluid buildup in the lungs as a result of heart failure. Cardiac asthma can be potentially life ...